The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 03, 2025
Filed:
Apr. 06, 2020
Green Cross Corporation, Yongin-si, KR;
Mogam Institute for Biomedical Research, Yongin-si, KR;
Jae Chan Park, Yongin-si, KR;
Eun Jung Song, Yongin-si, KR;
So Jung Lim, Yongin-si, KR;
Jae-Chul Lee, Yongin-si, KR;
Hae Naem Kwon, Yongin-si, KR;
Su A Lee, Yongin-si, KR;
Ok Jae Lim, Yongin-si, KR;
Mun Kyung Kim, Yongin-si, KR;
Hyun Jung Cho, Yongin-si, KR;
Gil-Jung Kim, Yongin-si, KR;
Jee Won Lee, Yongin-si, KR;
Sung Keun Kim, Yongin-si, KR;
Jong Wha Won, Yongin-si, KR;
Shin A Jang, Yongin-si, KR;
GREEN CROSS CORPORATION, Yongin-si, KR;
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, Yongin-si, KR;
Abstract
A bispecific anti-GPNMB/anti-CD3 antibody specifically binds to CD3 (cluster of differentiation 3) and GPNMB (glycoprotein non-metastatic melanoma protein B) and uses thereof are disclosed. The bispecific antibody shows high affinity and specificity to CD3 and GPNMB and thus can induce death of cancer cells expressing GPNMB and inhibit proliferation thereof. Therefore, the bispecific antibody can be used as an effective therapeutic agent for cancers expressing GPNMB.